Posted by Michael Wonder on 18 Dec 2024
FDA approves ensartinib for ALK positive locally advanced or metastatic non-small cell lung cancer
18 December 2024 - Today, the FDA approved ensartinib (Ensacove, Xcovery) for adult patients with anaplastic lymphoma kinase (ALK) positive locally advanced or metastatic non-small cell lung cancer who have not previously received an ALK inhibitor.
Efficacy was evaluated in eXALT3, an open-label, randomised, active-controlled, multi-centre trial in 290 patients with locally advanced or metastatic ALK positive non-small cell lung cancer who had not previously received an ALK targeted therapy.
